PRESS RELEASE
Obalon Engages Canaccord Genuity to Explore Financial and Strategic Alternatives
The overall uncertainty, the restriction on elective procedures and the specific directives issued by the Governor of
As a result of the
The impact of the Covid-19 crisis has significantly impacted Obalon’s stock price, stockholder value and its ability to access additional capital. Although Obalon ended
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits and those related to potential financial and strategic alternatives. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended
For
Investor Contact:
President and Chief Executive Officer
Office: +1 760 607 5103
wplovanic@obalon.com
Source: Obalon Therapeutics, Inc.